Center types in District of Columbia
Academic MS Center (1)
Community Hospital Program (1)
Filter by type:All (2)Academic MS Center (1)Community Hospital Program (1)
50% of MS centers in District of Columbia are classified as Academic MS Center facilities.
Centers with Most Active Trials in District of Columbia
Ranked by active clinical trial count from ClinicalTrials.gov. Not a quality ranking.
Largest Care Teams in District of Columbia
2. MedStar Washington Hospital Center1 provider
Compare MS Centers in District of Columbia
| Center | Type | Infusion | Virtual | Experience |
|---|---|---|---|---|
| Academic MS Center | — | — | 3.2/5 | |
MedStar Washington Hospital Center Washington | Community Hospital Program | — | — | 3.4/5 |
Active MS clinical trials in District of Columbia
See all 20 trials →ActivePhase 3
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
Novartis Pharmaceuticals
Washington D.C.
ActivePhase 3
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Novartis Pharmaceuticals
Washington D.C. · Washington D.C.
ActivePhase 3
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
Hoffmann-La Roche
Washington D.C.
ActivePhase 3
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
Novartis Pharmaceuticals
Washington D.C.
ActivePhase 3
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Hoffmann-La Roche
Washington D.C.
ActivePhase 3
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Novartis Pharmaceuticals
Washington D.C.
ActivePhase 3
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Hoffmann-La Roche
Washington D.C.
ActivePhase 3
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Sanofi
Washington D.C.
Check out the MS Buddy App
It's free, no ads. How? It's made and supported by MS patients who get their ideas from other MS patients.
